Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non‐plaque psoriasis

Maza, A.; Montaudié, Henri; Sbidian, É.; Gallini, Adeline; Aractingi, S.; Aubin, F.; Bachelez, Hervé; Cribier, B.; Joly, P.; Jullien, D.; Maître, Michel; Miséry, Laurent; Richard, M.‐A.; Jp, Ortonne; Paul, C.

doi:10.1111/j.1468-3083.2011.03992.x

Cited by 110 publications

(71 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies have shown that obesity is a risk factor for adverse events in patients treated with cyclosporine, especially if other risk factors are present, such as advanced age, concomitant use of nephrotoxic drugs, and hypertension. In such cases, the cyclosporine should be dosed according to ideal weight and not actual weight [64] . Interestingly, adi-posity also appears to affect the effectiveness of treatment with cyclosporine on the severity of psoriasis.…”

Section: Impact Of Obesity On the Treatment Of Psoriasismentioning

confidence: 99%

Psoriasis and Obesity

2016

View full text Add to dashboard Cite

Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis consisting of a genetic component, immune dysfunction, and environmental factors. It is associated with numerous comorbidities including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and obesity. Evidence suggests that obesity is a risk factor for incident psoriasis, aggravates existing psoriasis, and that weight reduction may improve the severity of psoriasis in overweight individuals. Excess body weight may interfere with the medical treatment used in psoriasis and adds to the cardiovascular risk profile in these patients, which underscores the importance of effective weight control regimens. In this review we examine the current literature with regard to the association between obesity and psoriasis.

show abstract

Section: Impact Of Obesity On the Treatment Of Psoriasismentioning

confidence: 99%

Psoriasis and Obesity

2016

View full text Add to dashboard Cite

show abstract

“…À la dose de 2,5 mg/kg par jour, entre 30 et 60 % des patients vont avoir 75 % ou plus d'amélioration du PASI. À la dose de 5 mg/kg par jour, entre 50 et 90 % des patients vont avoir 75 % d'amélioration du PASI [35]. À l'arrêt du traitement qui peut être brutal, la rechute du psoriasis survient en moyenne en trois à quatre mois [11,36].…”

Section: Ciclosporineunclassified

Traitement du psoriasis en pratique pour le rhumatologue

Paul

Bachelez

psoriasis³

2011

Revue du Rhumatisme Monographies

View full text Add to dashboard Cite

“…Eighty-nine percent and 50% of subjects with palmoplantar pustulosis and erythrodermic psoriasis obtained satisfactory effects after treatment with cyclosporin. 93 …”

Section: Cyclosporin Amentioning

confidence: 99%

Epidemiology and treatment of psoriasis: a Chinese perspective

Pan¹,

Zhang²

2014

PTT

View full text Add to dashboard Cite

Background: Psoriasis is a chronic inflammatory skin disease that has a negative impact on quality of life. Prevalence and management of psoriasis varies among different ethnic groups. Objectives: To evaluate the epidemiology and treatment of psoriasis from a Chinese perspective. Methods: A systematic search was performed on PubMed and the China National Knowledge Infrastructure using the following MeSH terms: "psoriasis" and ("prevalence" or "epidemiology") and "risk factor" and ("management" or "treatment"). The search included all citations from 1975 to 2013. Data were sorted by prevalence, age of onset, sex distribution, type, severity, risk factors, and management and treatment. Severity of psoriasis was classified as mild, moderate, or severe. The studies cited in this review involved Chinese subjects. Results: The prevalence of psoriasis in the People's Republic of China ranged from 0.11% to 0.47%. Genetic and environmental factors played an important role in initiation and exacerbation of psoriasis. Results showed that psoriasis can occur at any age but is more common in young and middle-aged individuals and occurs more often in men and earlier in women. Psoriasis vulgaris accounted for 82.6%-97.1% of psoriasis patients. More than 90% of patients with psoriasis were classified as mild or moderately severe. Risk factors are numerous. Management and treatment was based on classification level. Conclusion:The prevalence of psoriasis in Chinese patients is lower than that in Caucasians. A cold and dry climate, bacterial infection, diet, and stress are important risk factors for developing psoriasis. There are a variety of management and treatment options available. As such, Chinese patients with psoriasis can receive effective, safe, and individualized treatment.

show abstract

Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non‐plaque psoriasis

Cited by 110 publications

References 39 publications

Psoriasis and Obesity

Psoriasis and Obesity

Traitement du psoriasis en pratique pour le rhumatologue

Epidemiology and treatment of psoriasis: a Chinese perspective

Contact Info

Product

Resources

About